Structure Therapeutics Inc.
Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. Its lead product candidate is GSBR-1290, an oral and biased small…
Biotechnology
US, South San Francisco [HQ]
Ratios
4 Records · Starting from 2020Margins, Growth Rates In %
| Ratio | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Profitability | |||||
| Gross Margin | - - | - - | - - | - - | |
| Profit Margin | - - | - - | - - | - - | |
| Operating Margin | - - | - - | - - | - - | |
|
EPS Growth
|
- - | -150.00 | -139,900.00 | -74.29 | |
| EPS USD | -0.04 | -0.10 | -140.00 | -244.00 | |
| Return on Assets (ROA) | -41.02 | -34.23 | -52.45 | -18.58 | |
| Return on Equity (ROE) | 70.66 | 58.78 | 44.57 | -19.77 | |
| Return on Invested Capital (ROIC) | 72.31 | 59.15 | 45.77 | -22.46 | |
| Solvency | |||||
| Equity Ratio | - - | - - | -100 | - - | |
| Debt/Assets | 0.72 | 0.56 | 0.27 | 1.13 | |
| Debt/Equity | -1.25 | -0.96 | -0.23 | 1.20 | |
| Debt/EBITDA | 101.04 | 278.24 | 172.34 | 122.22 | |
|
Debt/Capitalization
|
-1.26 | -0.97 | -0.23 | 1.19 | |
| Long-Term Debt/Capitalization | -0.60 | -0.42 | - - | 0.88 | |
| Interest Debt per Share USD | - - | - - | -0.03 | 0.51 | |
| Debt Growth | - - | 121.79 | 41,767.96 | 1,997.31 | |
| Liquidity | |||||
| Current Ratio | 1,264.20 | 1,261.84 | 715.52 | 1,914.34 | |
| Quick Ratio | 1,232.15 | 1,239.40 | 1,195.93 | 1,888.94 | |
| Cash Ratio | 538.07 | 1,216.27 | 698.24 | 524.62 | |
| Operating Cash Flow Ratio | -400 | -300 | -300 | -300 | |
| Turnover | |||||
| Inventory Turnover | - - | - - | - - | - - | |
| Receivables Turnover | - - | - - | - - | - - | |
| Payables Turnover | 1.31 | 7.65 | 10.37 | 20.02 | |
|
Asset Turnover
|
- - | - - | - - | - - | |
| Fixed Turnover | - - | - - | - - | - - | |
| Coverage | |||||
| Interest Coverage | - - | -30.86 | 3,426.40 | -766.83 | |
| Asset Coverage | 12,700 | 16,500 | 32,700 | 8,400 | |
| Cash Flow Coverage (CFGR) | -5,101.07 | -5,178.74 | -17,738.46 | -1,456.43 | |
| EBITDA Coverage | - - | - - | 3,400 | -700 | |
| Dividend Coverage | - - | - - | - - | - - | |
| Time Interest Earned (TIE) | -100 | -700 | - - | - - | |
| Market Prospects | |||||
| Dividend Yield | - - | - - | - - | - - | |
| Earnings Yield | - - | - - | -5.40 | -5.98 | |
|
Price/Earnings (P/E)
|
-59,920.2836 | -25,001.8245 | -18.5362 | -16.7209 | |
| Price/Earnings Growth (PEG) | - - | -16,667.88 | -0.01 | -22.51 | |
|
Price/Book (P/B)
|
-4,233,808.46 | -1,469,521.00 | -826.21 | 330.54 | |
| Price/Tangible Book (P/TB) | -4,233,808.46 | -1,469,521.00 | -826.21 | 330.54 | |
| Price/Sales (P/S) | - - | - - | - - | - - | |
|
Price/Cash Flow (P/CF)
|
-6,660,326.42 | -2,958,005.04 | -2,062.65 | -1,885.22 | |
| Price/Free CF (P/FCF) | -6,651,478.27 | -2,851,089.20 | -2,055.74 | -1,835.19 | |
| Price/Operating CF (P/OCF) | -6,660,326.42 | -2,958,005.04 | -2,062.65 | -1,885.22 |